Stock Alert: PDS Biotechnology Shares Up 7%

Shares of PDS Biotechnology Corp. (PDSB) are rising over 7% Monday morning, after the company announced robust preclinical data for its COVID-19 vaccine candidate, Versamune-CoV-2 (PDS0203).

The company noted that PDS0203 pairs the Versamune platform with a recombinant protein recognized by the human immune system that is derived from the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus that causes COVID-19.

The protein included in PDS0203 encompasses SARS-CoV-2 sections that induce an antibody response, as well as sections that are recognized by CD8 and CD4 T-cells.

PDS Biotech has generated robust preclinical data confirming that PDS0203 elicits induction of highly active and potent virus-specific CD8 killer and CD4 helper T-cells within 14 days of treatment. Further, PDS Biotech said it plans to submit details of the preclinical studies to a peer reviewed scientific journal.

The stock has been trading in the range of $0.61 - $6.71 for the past one year, and is currently trading at $3.84, up 26 cents or 7.26%.

For comments and feedback contact: editorial@rttnews.com

Business News

Looking to Invest in the Best Biotech Stocks? Subscribe to RTT Biotech Investor.
Follow RTT